ADPT

SEC source: 0001209191-20-009857 · doc4.xml · derivative · entry 1

NEUPERT PETER M · CIK 0001237566 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,888

Underlying: Common Stock · 8,888 shares

Expires 2030-02-13

F1 · derivative.exercise_date: The option will vest in equal monthly installments over one year, subject to continued service as a director through such vesting date.

SEC source: 0000902664-20-002039 · ownership.xml · derivative · entry 1

GOEL DAVID E. · CIK 0001548144 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,888

Underlying: Common Stock · 8,888 shares

Expires 2030-02-13

F1 · derivative.exercise_date: The option will vest in equal monthly installments over one year, subject to continued service as a director through such vesting date.

F2 · ownership.direct: The filing of this statement shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. The Reporting Person expressly disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.

SEC source: 0001209191-20-009038 · doc4.xml · derivative · entry 8

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 724,000

Underlying: Common Stock · 11,200 shares

Expires 2021-12-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F5 · derivative.exercise_date: The options are fully vested and exercisable.

SEC source: 0001209191-20-009038 · doc4.xml · nonDerivative · entry 4

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,878,180

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $30.88 to 31.51, inclusive.

SEC source: 0001209191-20-009038 · doc4.xml · nonDerivative · entry 3

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,889,300

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

SEC source: 0001209191-20-009038 · doc4.xml · derivative · entry 7

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 735,200

Underlying: Common Stock · 11,200 shares

Expires 2021-12-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F5 · derivative.exercise_date: The options are fully vested and exercisable.

SEC source: 0001209191-20-009038 · doc4.xml · nonDerivative · entry 2

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,878,180

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $30.78 to 31.72, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001209191-20-009038 · doc4.xml · nonDerivative · entry 1

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,889,300

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

SEC source: 0001209191-20-008927 · doc4.xml · derivative · entry 4

Cohen Chad M · CIK 0001524314 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 20,000 shares

Expires 2025-03-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2019.

F4 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001209191-20-008927 · doc4.xml · nonDerivative · entry 3

Cohen Chad M · CIK 0001524314 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,000

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2019.

F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $30.81 to 31.80, inclusive.

SEC source: 0001209191-20-008927 · doc4.xml · nonDerivative · entry 2

Cohen Chad M · CIK 0001524314 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,721

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2019.

F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $31.81 to 32.20, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001209191-20-008927 · doc4.xml · nonDerivative · entry 1

Cohen Chad M · CIK 0001524314 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2019.

SEC source: 0001209191-20-005417 · doc4.xml · derivative · entry 12

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 746,400

Underlying: Common Stock · 11,200 shares

Expires 2021-12-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F7 · derivative.exercise_date: The options are fully vested and exercisable.

SEC source: 0001209191-20-005417 · doc4.xml · nonDerivative · entry 7

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,878,180

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F5 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $30.68 to 31.58, inclusive.

SEC source: 0001209191-20-005417 · doc4.xml · nonDerivative · entry 6

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,889,300

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

SEC source: 0001209191-20-005416 · doc4.xml · derivative · entry 3

ZOLTNERS ANDRIS A · CIK 0001780665 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 100,000 shares

Expires 2020-02-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The shares are fully vested and exercisable.

SEC source: 0001209191-20-005416 · doc4.xml · nonDerivative · entry 2

ZOLTNERS ANDRIS A · CIK 0001780665 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,621,016

SEC source: 0001209191-20-005416 · doc4.xml · nonDerivative · entry 1

ZOLTNERS ANDRIS A · CIK 0001780665 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,966,016

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-20-005417 · doc4.xml · derivative · entry 11

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 757,600

Underlying: Common Stock · 11,200 shares

Expires 2021-12-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F7 · derivative.exercise_date: The options are fully vested and exercisable.

SEC source: 0001209191-20-005417 · doc4.xml · nonDerivative · entry 5

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,878,180

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $31.68 to 32.03, inclusive.

SEC source: 0001209191-20-005417 · doc4.xml · nonDerivative · entry 4

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,878,980

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $30.67 to 31.66, inclusive.

SEC source: 0001209191-20-005417 · doc4.xml · nonDerivative · entry 3

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,889,300

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

SEC source: 0000903423-20-000010 · adaptive.xml · nonDerivative · entry 1

VIKING GLOBAL INVESTORS LP · CIK 0001103804 · 10% owner

Viking Global Opportunities Illiquid Investments Sub-Master LP · CIK 0001629482 · 10% owner

Viking Global Opportunities Portfolio GP LLC · CIK 0001629472 · 10% owner

Viking Global Opportunities GP LLC · CIK 0001629476 · 10% owner

HALVORSEN OLE ANDREAS · CIK 0001133006 · 10% owner

Ott David C. · CIK 0001621842 · 10% owner

Shabet Rose Sharon · CIK 0001711393 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See explanation of responses

Disclosed balance after: 33,493,708

F1 · shares: On January 28, 2020, the Viking Funds (defined below) sold an aggregate of 4,912,899 shares of common stock of the Issuer ("Common Stock") at a price of $24.9763 per share in connection with the Issuer's secondary offering (the "Secondary Offering"). VGE II sold 69,386 shares in the Secondary Offering, VGEM sold 3,399,929 shares in the Secondary Offering, VLFM sold 1,260,106 shares in the Secondary Offering and Opportunities Fund sold 183,478 shares in the Secondary Offering.

F2 · ownership.nature: O. Andreas Halvorsen, David C. Ott and Rose S. Shabet are Executive Committee members of certain management entities, including Viking Global Partners LLC, the general partner of Viking Global Investors LP ("VGI"), Viking Global Performance LLC ("VGP"), Viking Long Fund GP LLC ("VLFGP") and Viking Global Opportunities GP LLC ("Opportunities GP"), the sole owner of Viking Global Opportunities Portfolio GP LLC ("Opportunities Portfolio GP"). VGI provides managerial services to various investment funds, including Viking Global Equities II LP ("VGE II"), Viking Global Equities Master Ltd. ("VGEM"), Viking Long Fund Master Ltd. ("VLFM") and Viking Global Opportunities Illiquid Investments Sub-Master LP ("Opportunities Fund," and together with VLFM, VGEM and VGE II, the "Viking Funds").

F3 · ownership.nature: VGP is the general partner of VGE II. Opportunities Portfolio GP is the general partner of Opportunities Fund. VLFGP serves as the investment manager of VLFM. Each of the Viking Funds, VGI, VGP, VLFGP, Opportunities Portfolio GP, Mr. Halvorsen, Mr. Ott and Ms. Shabet (collectively, the "Reporting Persons") may be deemed to beneficially own the shares reported on this form.

F4 · ownership.nature: VGI provides managerial services to (i) VGE II, which directly holds 473,043 shares of Common Stock; (ii) VGEM, which directly holds 23,179,034 shares of Common Stock; (iii) VLFM, which directly holds 8,590,772 shares of Common Stock; and (iv) Opportunities Fund, which directly holds 1,250,859 shares of Common Stock. Because of the relationship between VGI and the Viking Funds, VGI may be deemed to beneficially own the shares of Common Stock directly held by the Viking Funds.

F5 · ownership.nature: VGP is the general partner of VGE II and the investment manager of VGEM. Because of the relationships between VGP and VGE II and VGEM, respectively, VGP may be deemed to beneficially own the shares of Common Stock directly held by VGE II and VGEM.Common Stock; (iii) VLFM, which directly holds 9,850,878 shares of Common Stock; and (iv) Opportunities Fund, which directly holds 1,434,337 shares of Common Stock. Because of the relationship between VGI and the Viking Funds, VGI may be deemed to beneficially own the shares of Common Stock directly held by the Viking Funds.

F6 · ownership.nature: VLFGP serves as the investment manager of VLFM. Because of the relationship between VLFGP and VLFM, VLFGP may be deemed to beneficially own the shares of Common Stock directly held by VLFM.

F7 · ownership.nature: Opportunities Portfolio GP is the general partner of Opportunities Fund. Because of the relationship between Opportunities Portfolio GP and Opportunities Fund, Opportunities Portfolio GP may be deemed to beneficially own the shares of Common Stock held directly by Opportunities Fund. Opportunities GP is the sole owner of Opportunities Portfolio GP. Because of the relationship between Opportunities GP and Opportunities Portfolio GP, Opportunities GP may be deemed to beneficially own the shares of Common Stock held directly by Opportunities Fund.

F8 · ownership.nature: The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.Opportunities Fund, Opportunities Portfolio GP may be deemed to beneficially own the shares of Common Stock held directly by Opportunities Fund. Opportunities GP is the sole owner of Opportunities Portfolio GP. Because of the relationship between Opportunities GP and Opportunities Portfolio GP, Opportunities GP may be deemed to beneficially own the shares of Common Stock held directly by Opportunities Fund.

SEC source: 0000903423-20-000011 · vgpadaptive4.xml · nonDerivative · entry 1

VIKING GLOBAL PERFORMANCE LLC · CIK 0001132625 · 10% owner

Viking Global Equities II LP · CIK 0001413378 · 10% owner

Viking Global Equities Master Ltd. · CIK 0001759530 · 10% owner

Viking Long Fund GP LLC · CIK 0001621607 · 10% owner

Viking Long Fund Master Ltd. · CIK 0001621596 · 10% owner

HALVORSEN OLE ANDREAS · CIK 0001133006 · 10% owner

Ott David C. · CIK 0001621842 · 10% owner

Shabet Rose Sharon · CIK 0001711393 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See explanation of responses

Disclosed balance after: 33,493,708

F1 · shares: On January 28, 2020, the Viking Funds (defined below) sold an aggregate of 4,912,899 shares of common stock of the Issuer ("Common Stock") at a price of $24.9763 per share in connection with the Issuer's secondary offering (the "Secondary Offering"). VGE II sold 69,386 shares in the Secondary Offering, VGEM sold 3,399,929 shares in the Secondary Offering, VLFM sold 1,260,106 shares in the Secondary Offering and Opportunities Fund sold 183,478 shares in the Secondary Offering.

F2 · ownership.nature: O. Andreas Halvorsen, David C. Ott and Rose S. Shabet are Executive Committee members of certain management entities, including Viking Global Partners LLC, the general partner of Viking Global Investors LP ("VGI"), Viking Global Performance LLC ("VGP"), Viking Long Fund GP LLC ("VLFGP") and Viking Global Opportunities GP LLC ("Opportunities GP"), the sole owner of Viking Global Opportunities Portfolio GP LLC ("Opportunities Portfolio GP"). VGI provides managerial services to various investment funds, including Viking Global Equities II LP ("VGE II"), Viking Global Equities Master Ltd. ("VGEM"), Viking Long Fund Master Ltd. ("VLFM") and Viking Global Opportunities Illiquid Investments Sub-Master LP ("Opportunities Fund," and together with VLFM, VGEM and VGE II, the "Viking Funds").

F3 · ownership.nature: VGP is the general partner of VGE II. Opportunities Portfolio GP is the general partner of Opportunities Fund. VLFGP serves as the investment manager of VLFM. Each of the Viking Funds, VGI, VGP, VLFGP, Opportunities Portfolio GP, Mr. Halvorsen, Mr. Ott and Ms. Shabet (collectively, the "Reporting Persons") may be deemed to beneficially own the shares reported on this form.

F4 · ownership.nature: VGI provides managerial services to (i) VGE II, which directly holds 473,043 shares of Common Stock; (ii) VGEM, which directly holds 23,179,034 shares of Common Stock; (iii) VLFM, which directly holds 8,590,772 shares of Common Stock; and (iv) Opportunities Fund, which directly holds 1,250,859 shares of Common Stock. Because of the relationship between VGI and the Viking Funds, VGI may be deemed to beneficially own the shares of Common Stock directly held by the Viking Funds.

F5 · ownership.nature: VGP is the general partner of VGE II and the investment manager of VGEM. Because of the relationships between VGP and VGE II and VGEM, respectively, VGP may be deemed to beneficially own the shares of Common Stock directly held by VGE II and VGEM.

F6 · ownership.nature: VLFGP serves as the investment manager of VLFM. Because of the relationship between VLFGP and VLFM, VLFGP may be deemed to beneficially own the shares of Common Stock directly held by VLFM.

F7 · ownership.nature: Opportunities Portfolio GP is the general partner of Opportunities Fund. Because of the relationship between Opportunities Portfolio GP and Opportunities Fund, Opportunities Portfolio GP may be deemed to beneficially own the shares of Common Stock held directly by Opportunities Fund. Opportunities GP is the sole owner of Opportunities Portfolio GP. Because of the relationship between Opportunities GP and Opportunities Portfolio GP, Opportunities GP may be deemed to beneficially own the shares of Common Stock held directly by Opportunities Fund.

F8 · ownership.nature: The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

SEC source: 0001209191-20-005417 · doc4.xml · derivative · entry 10

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 768,800

Underlying: Common Stock · 11,200 shares

Expires 2021-12-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F7 · derivative.exercise_date: The options are fully vested and exercisable.

SEC source: 0001209191-20-005417 · doc4.xml · nonDerivative · entry 2

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,878,180

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $29.70 to 30.32, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001209191-20-005417 · doc4.xml · nonDerivative · entry 1

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,889,300

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

SEC source: 0000902664-20-000523 · ownership.xml · nonDerivative · entry 1

GOEL DAVID E. · CIK 0001548144 · Director · 10% owner · See Remarks

Matrix Capital Management Company, LP · CIK 0001410830 · Director · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 15,115,090

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F2 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

SEC source: 0001209191-20-004113 · doc4.xml · derivative · entry 14

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 588,900

Underlying: Common Stock · 3,700 shares

Expires 2025-06-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F8 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001209191-20-004113 · doc4.xml · nonDerivative · entry 9

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,679

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F7 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $28.09 to 28.66, inclusive.

SEC source: 0001209191-20-004113 · doc4.xml · nonDerivative · entry 8

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,079

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F6 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $27.11 to 27.89, inclusive.

SEC source: 0001209191-20-004113 · doc4.xml · nonDerivative · entry 7

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,379

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

SEC source: 0001209191-20-004113 · doc4.xml · derivative · entry 13

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 592,600

Underlying: Common Stock · 3,700 shares

Expires 2025-06-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F8 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001209191-20-004113 · doc4.xml · nonDerivative · entry 6

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,679

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F5 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $29.40 to 29.69, inclusive.

SEC source: 0001209191-20-004113 · doc4.xml · nonDerivative · entry 5

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,979

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $28.40 to 29.39, inclusive.

SEC source: 0001209191-20-004113 · doc4.xml · nonDerivative · entry 4

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,279

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $27.39 to 28.31, inclusive.

SEC source: 0001209191-20-004113 · doc4.xml · nonDerivative · entry 3

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,379

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

SEC source: 0001209191-20-004113 · doc4.xml · derivative · entry 12

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 596,300

Underlying: Common Stock · 3,700 shares

Expires 2025-06-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F8 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001209191-20-004113 · doc4.xml · nonDerivative · entry 2

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,679

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $29.25 to 29.74, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001209191-20-004113 · doc4.xml · nonDerivative · entry 1

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,379

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

SEC source: 0001209191-20-003083 · doc4.xml · derivative · entry 3

Taylor Stacy L · CIK 0001799081 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 52,662 shares

Expires 2028-04-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F2 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 12, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001209191-20-003083 · doc4.xml · nonDerivative · entry 2

Taylor Stacy L · CIK 0001799081 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,300

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

SEC source: 0001209191-20-003083 · doc4.xml · nonDerivative · entry 1

Taylor Stacy L · CIK 0001799081 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,962

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

SEC source: 0001209191-20-003081 · doc4.xml · derivative · entry 3

Cohen Chad M · CIK 0001524314 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 20,000 shares

Expires 2025-03-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2019.

F3 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001209191-20-003081 · doc4.xml · nonDerivative · entry 2

Cohen Chad M · CIK 0001524314 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,000

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2019.

F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $29.43 to 30.25, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001209191-20-003081 · doc4.xml · nonDerivative · entry 1

Cohen Chad M · CIK 0001524314 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2019.

SEC source: 0001209191-20-009865 · doc4a.xml · derivative · entry 3

Taylor Stacy L · CIK 0001799081 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,000

Underlying: Common Stock · 52,662 shares

Expires 2028-04-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F2 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 12, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001209191-20-009865 · doc4a.xml · nonDerivative · entry 2

Taylor Stacy L · CIK 0001799081 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,300

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

SEC source: 0001209191-20-009865 · doc4a.xml · nonDerivative · entry 1

Taylor Stacy L · CIK 0001799081 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,962

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

SEC source: 0001209191-20-002419 · doc4.xml · derivative · entry 6

HILL NANCY LOUISE · CIK 0001780790 · SVP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 140,000

Underlying: Common Stock · 60,000 shares

Expires 2023-11-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 5, 2019.

F4 · derivative.exercise_date: The option is fully vested and exercisable.